Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GPC Biotech has reported that the company has been informed by its partner for satraplatin in Europe that they plan to withdraw the marketing authorization application for satraplatin plus prednisone for the treatment of hormone-refractory prostate cancer patients whose prior chemotherapy has failed.
Subscribe to our email newsletter
This decision was based on a list of outstanding issues received following review by the Committee for Medicinal Products for Human Use of the European Medicines Agency of the filing, which indicates that the opinion of the committee is that the application is currently not approvable based on the information provided.
Bernd Seizinger, CEO of GPC Biotech, said: “Although we previously communicated that the approval of the marketing authorization application for satraplatin would be challenging, today’s outcome is nevertheless disappointing.
“We are working closely with our partners to determine the next steps regarding the development of satraplatin and continue to focus our other efforts on advancing our RGB-286638 kinase inhibitor into the clinic and exploring various merger and acquisition opportunities.”